A Multi-center, Randomized, Double-blind, Vehicle-Controlled, Phase 2 Study of the Safety and Efficacy of Benzoyl peroxide/Clindamycin gel and Tazarotene cream when used in combination in the Treatment of Acne Vulgaris.

GlaxoSmithKline Research & Development0 个研究点目标入组 591 人开始时间: 2016年12月21日最近更新: 2017年1月9日

试验速览

暂无简介。

•- Subjects must be males or females 12 to 45 years of age.
•- Subjects must have acne on their face.
•- Female subjects of childbearing potential must have a negative pregnancy test. If sexually active, one medically acceptable forms of contraception must be practiced from baseline to the last study visit.
•- Subjects must have the ability and willingness to follow all study procedures, attend all scheduled visits, and successfully complete the study.
•- Subjects must be capable of understanding and willing to provide signed and dated written voluntary informed consent (and any local or national authorization requirements).
•- Subjects must be able to complete the study and to comply with study instructions.
•Are the trial subjects under 18? yes
•Number of subjects for this age range: 301
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range 286
•F.1.3 Elderly (>=65 years) no
•F.1.3.1 Number of subjects for this age range

•- Subjects who are pregnant, trying to become pregnant, or breast-feeding.
•- Subjects with conditions that may influence the safety and or efficacy assessments of the study including, but not limited to: regional enteritis or inflammatory bowel disease, lupus, dermatomyositis, rosacea, seborrheic dermatitis, beard folliculitis, or perioral dermatitis, subject who are immunocompromised or have had any major illness within 30 days before the screening examination
•- History of known or suspected intolerance including any known hypersensitivity or previous allergic reaction to any of the ingredients of the study products
•- Subjects who have used topical antibiotics or topical steroids on the face, facial procedures, or any investigational therapy within the past 4 weeks or systemic retinoids within the past 6 months.
•- Subjects who have any other disease or condition, or are using any medication, that in the judgment of the investigator would put the subject at unacceptable risk for participation in the study.
•- Other exclusion criteria may apply.

发起方